The BRAFV600E mutation has been a significant biomarker for early diagnosis of thyroid cancer.5, 6 In 2013, TERT promoter mutations C228T and C250T were discovered, which represents another significant milestone in the field of thyroid cancer.7 A strong synergistic effect on the insistence of thyroid cancer happened in the co‐occurrence of TERT and BRAF V600E promoter mutations, which has been using for the early finding and optimal management of thyroid cancer. This evidence concerns the gene TERT and thyroid gland carcinoma.